12 results about "Hypoglycemic product" patented technology

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention belongs to the technical field of biology, and particularly relates to a bifidobacterium longum subsp. Longum FMBL B241768LS, a microbial inoculum and application of the microbial inoculum in hypoglycemic products, the bifidobacterium longum subsp. Longum FMBL B241768LS is preserved in China Center for Type Culture Collection on October 14, 2024, and the preservation number is CCTCC NO: M 20242173; the inhibitory activity of the compound on dipeptidyl peptidase IV is as high as 79.17%; the compound has a relatively good inhibition effect on the activity of alpha-glucosidase and alpha-amylase; the compound shows drug resistance to ciprofloxacin, ampicillin, penicillin G, clindamycin, kanamycin and polymyxin B; a good inhibition effect is achieved on pathogenic bacteria; the strain can be used for preparing medicines, fermented foods, health-care products and food additives for reducing blood sugar and inhibiting pathogenic bacteria, and has a wide application prospect.

This invention belongs to the field of biotechnology, specifically relating to an α-glucosidase inhibitory peptide and its applications. The invention uses oat bran as raw material to extract protein, prepares oat bioactive peptides through enzymatic hydrolysis, and uses bioinformatics analysis to screen for the α-glucosidase inhibitory peptide RELGGFF, which exhibits an IC50 value of 531.90±5.23 μg / mL against α-glucosidase. Furthermore, the inhibitory effect of the combined use of the α-glucosidase inhibitory peptide RELGGFF and oat β-glucan on α-glucosidase activity is investigated, and its application can be explored in the preparation of products that inhibit α-glucosidase activity, in the preparation of hypoglycemic products, or in the preparation of products for treating diabetes.

The invention provides a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of hypoglycemic products, and relates to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials: 4-8 parts of ginseng stem and leaf saponin, 8-16 parts of astragalus polysaccharide, 6-12 parts of astragaloside, 8-16 parts of catalpol, 6-12 parts of rehmannia D, 8-16 parts of verbascoside, 3-5 parts of raspberry polysaccharide, 4-8 parts of ellagic acid, 4-8 parts of pachymaran, 5-10 parts of pachymic acid, 8-16 parts of lycium barbarum polysaccharide, 40-62 parts of schisandra chinensis, 20-40 parts of Chinese yam, 40-62 parts of radix ophiopogonis, 40-62 parts of radix trichosanthis and 40-62 parts of rhizoma alismatis. The traditional Chinese medicine raw materials are pretreated by using the high-voltage pulsed electric field, and then ethanol extraction treatment is performed twice, so that the yield of the traditional Chinese medicine extract is high, and the traditional Chinese medicine composition obtained by mixing the traditional Chinese medicine extract with other active ingredients has an excellent effect of treating type II diabetes mellitus.

The application discloses application of Akkermansia muciniphila in preparation of a hypoglycemic product. Experiments prove that the Akkermansia muciniphila is Akkermansia muciniphila AkkTimepie001 with a preservation number of CCTCC NO: M 20231906, can effectively increase the body weight of a type 2 diabetes model mouse, improve the glucose tolerance capacity of the type 2 diabetes model mouse, and reduce the fasting blood glucose level, and confirms that the Akkermansia muciniphila has a significant blood glucose lowering effect.

Provided is use of scavenger receptor class A member 3 or a reagent increasing the expression of scavenger receptor class A member 3 in preparing a hypoglycemic product. By means of overexpressing a human-derived SR-A3 gene in hamsters, it was found that the overexpression of the human-derived SR-A3 gene can reduce the plasma glucose concentration, decrease the plasma insulin concentration, improve glucose tolerance, enhance insulin sensitivity, reduce insulin resistance, lower the expression of gluconeogenesis-related genes, and inhibit the activation of the AKT signaling pathway. The present application provides a new target and a new strategy for the precise treatment of patients with hyperglycemia.

The invention provides an eucommia male flower extract for reducing postprandial blood sugar and a preparation method of the eucommia male flower extract, and belongs to the technical field of plant active substance extraction. The eucommia male flower extract capable of effectively inhibiting alpha-amylase and alpha-glucosidase is obtained through a specific preparation method, and a new thought and approach are provided for developing hypoglycemic products. The eucommia male flower extract provided by the invention shows a good treatment effect on reducing postprandial blood sugar, can obviously reduce postprandial blood sugar levels of normal mice and type 2 diabetes mellitus mice mediated by starch and glucose, reduces an area value under a corresponding curve, and improves oral starch sugar tolerance and glucose sugar tolerance of the mice. Therefore, the eucommia male flower extract disclosed by the invention can be applied to preparation of products for reducing blood sugar.

The invention relates to the technical field of biological science, and discloses a plant lactobacillus microencapsulated preparation and application of the plant lactobacillus microencapsulated preparation in preparation of a hypoglycemic product, and the plant lactobacillus microencapsulated preparation is prepared from plant lactobacillus XKFY202518. The preservation number of the plant lactobacillus XKFY202518 in the China General Microbiological Culture Collection Center (CGMCC) is CGMCC No.34745, and the preservation date of the plant lactobacillus XKFY202518 is June 3, 2025. According to the invention, the plant lactobacillus microencapsulated preparation is compounded with the white kidney bean extract, the mulberry leaf extract and the prebiotics to form a triple synergistic system of probiotic metabolism regulation, enzyme inhibitor targeted sugar control and prebiotics colonization promotion. All the components are good in compatibility, no effect antagonism phenomenon exists, not only can different sugar control links such as amylolysis and disaccharide absorption be covered, but also intestinal colonization of probiotics can be promoted, and the overall effects of reducing blood sugar and improving lipid metabolism are remarkably improved.

The invention discloses dandelion polysaccharide with high hypoglycemic activity as well as a preparation method and application thereof. The preparation method comprises the following steps: drying, crushing and sieving whole dandelion plants, degreasing and decolorizing, extracting and concentrating the obtained pretreated powder by hot water, carrying out graded alcohol precipitation to obtain crude dandelion polysaccharide, screening the crude dandelion polysaccharide with optimal activity by virtue of oxidation resistance and in-vitro blood sugar reduction, deproteinizing, and separating and purifying by virtue of DEAE-52 and Sephadex G-200 to obtain relatively uniform dandelion polysaccharide. The dandelion polysaccharide can remarkably inhibit the activity of alpha-amylase and alpha-glucosidase, improve the glucose consumption capacity of IR-HepG2 cells (an insulin resistance model) and effectively reduce fasting blood glucose of type 2 diabetes mellitus mice, can be used for developing and preparing hypoglycemic products, and meanwhile, can be used for preparing hypoglycemic products. The fine structure characteristics of the dandelion polysaccharide with the hypoglycemic activity are further analyzed, and reference and data support are provided for development and application of dandelion and polysaccharide.

Provided are a Bacillus coagulans strain VHProbi C08 having a blood glucose reduction efficacy and an application thereof in preparation of a hypoglycemic product. The accession number of the strain is CCTCCM 2019738. Further provided is a hypoglycemic product comprising the Bacillus coagulans VHProbi C08 and / or the fermentation product of Bacillus coagulans VHProbi C08. A carbon source used in the culture medium of the strain is any one or more of fructooligosaccharide, galactooligosaccharides, and inulin.

The invention belongs to the technical field of probiotics, and particularly relates to a bacterial strain with a hypoglycemic effect and a culture method and application thereof.The bacterial strain with the hypoglycemic effect is obtained by conducting specific hypoglycemic induction culture on bifidobacterium animalis subsp. Lactis HN1000, the hypoglycemic activity is further improved, and the hypoglycemic effect is good. When the bacterial strain is applied to preparation of probiotic tablets as an auxiliary hypoglycemic product, the bacterial strain and bacillus coagulans synergistically play a biological hypoglycemic role under an enteric coating layer formed by whey protein and sodium alginate, the in-vivo activity of probiotics is greatly improved, and meanwhile, the in-vivo hypoglycemic effect of the probiotics is improved. And with other nutritional active components including mulberry leaf extract, galactooligosaccharide, resistant starch and microcrystalline cellulose, sugar absorption inhibition and insulin sensitivity improvement are realized.